ABP Stock Overview
A biotechnology company, provides antibody therapeutics for cancer related issues. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Abpro Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.37 |
| 52 Week High | US$13.00 |
| 52 Week Low | US$0.95 |
| Beta | -0.29 |
| 1 Month Change | -13.61% |
| 3 Month Change | -87.70% |
| 1 Year Change | -88.03% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -15.2% | -2.4% | -2.1% |
| 1Y | -88.0% | -8.7% | 21.3% |
Return vs Industry: ABP underperformed the US Biotechs industry which returned -6.4% over the past year.
Return vs Market: ABP underperformed the US Market which returned 23.2% over the past year.
Price Volatility
| ABP volatility | |
|---|---|
| ABP Average Weekly Movement | 37.3% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ABP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ABP's weekly volatility has increased from 23% to 37% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 16 | Miles Suk | abpro.com |
Abpro Holdings, Inc., a biotechnology company, provides antibody therapeutics for cancer related issues. Its platform DiversImmune addresses the antibody therapeutics. The company’s product candidates include ABP-102 for the treatment of breast and gastric cancer; and ABP-110 for the treatment of liver cancer.
Abpro Holdings, Inc. Fundamentals Summary
| ABP fundamental statistics | |
|---|---|
| Market cap | US$65.17m |
| Earnings (TTM) | -US$16.26m |
| Revenue (TTM) | US$122.00k |
565.3x
P/S Ratio-4.2x
P/E RatioIs ABP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABP income statement (TTM) | |
|---|---|
| Revenue | US$122.00k |
| Cost of Revenue | US$4.27m |
| Gross Profit | -US$4.14m |
| Other Expenses | US$12.11m |
| Earnings | -US$16.26m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | -3,396.72% |
| Net Profit Margin | -13,325.72% |
| Debt/Equity Ratio | -13.6% |
How did ABP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 09:47 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Abpro Holdings, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|